Report Description of the EU Osteoporosis Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for EU Osteoporosis Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU Osteoporosis Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

EU Osteoporosis Market Analysis Executive Summary

Osteoporosis is a complex, chronic disease that can be treated and managed in a number of ways. Improvements in medication and diagnostic techniques in the past 30 years have provided highly effective ways to reduce the risk of osteoporotic fractures. In Europe, however, research has shown significant heterogeneity in the different national approaches to the management of the disease.

Market Size and Key Findings

The EU Osteoporosis Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

Rank ligand inhibitors may also be used in conjunction with other drugs to give a synergistic effect on the overall treatment regimen. It is also anticipated that this factor will be one of the key factors responsible for presenting lucrative opportunities. Other advantages related to ligand rank Inhibitors such as decreased bone cell turnover and increased bone mineral density, resulting in high demand. The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.

Market Restraints

Growth in the market for osteoporosis drugs is likely to be delayed due to side effects and risks involved with osteoporosis medications. For e.g., heartburn, muscle and joint pain, diarrhea, and stomach or esophagus ulcers are risks associated with the drug class of bisphosphonates. Other than this, other classes of drugs also have side effects in patients. Many risks caused by osteoporosis medications include bone trauma, bone breaks, and urinary infection. Moreover, the patent expiry of new branded products and the restricted reimbursement by healthcare payers often adversely affect the growth of the market.

COVID-19 impact on "EU Osteoporosis Market Analysis

EU-funded consortium Exscalate4CoV has announced that an already registered generic drug used to treat osteoporosis, Raloxifene, could be an effective treatment for COVID-19 patients with mildly symptomatic infection. The consortium is using an EU-backed supercomputing platform, one of the worlds most powerful, to check the potential impact of known molecules against the genomic structure of coronavirus. This is one of many examples of how the EU's research and innovation programme Horizon 2020 is bringing together the best of European researchers, pharmaceutical companies, technologies and research infrastructures to contribute to defeating the virus.

Competitive Landscape

Key Players

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company.

Products in Pipeline

In 1994 and 2008, the WHO published diagnostic criteria for osteoporosis in postmenopausal women based on the T-score for bone mineral density (BMD). Osteoporosis is defined as a value for BMD 2.5 standard deviations (SD) or more below the young female adult mean (T-score less than or equal to 2.5 SD).

Notable Recent Deals

The scorecard for osteoporosis in Europe (SCOPE) is a project of the International Osteoporosis Foundation (IOF) that seeks to raise awareness of osteoporosis care in Europe. The aim of this project was to develop a scorecard and background documents to draw attention to gaps and inequalities in the provision of primary and secondary prevention of fractures due to osteoporosis.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

Health strategies across European countries have recognised the critical role of reducing frailty and maintaining mobility as part of healthy ageing and prevention. Yet osteoporosis does not usually appear in national prevention strategies. In policies for chronic disease, other conditions such as diabetes and heart disease have received considerably more attention from European policymakers. A recent analysis showed that musculoskeletal health, which includes osteoporosis and fragility fractures, was only included in half of non-communicable disease strategies for OECD countries. Few countries specifically address womens needs in national health policy. In those that do, osteoporosis is often absent despite its significant impact on womens health.